2185872-76-6
2185872-76-6
Chemical Structure
mDPR-Val-Cit-PAB-MMAE TFA
- CAS No.: 2185872-76-6
- Formula:C67H101F3N12O17
- Molecular Weight:1403.58
InChIKey: RXLQUNBHYABLPJ-GNTLDFNYSA-N
SMILES: CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)OC)=O)OC)N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C(OCC3=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC([C@@H](N4C(C=CC4=O)=O)CN)=O)=O)=O)C=C3)=O)C)=O)=O)C.O=C(O)C(F)(F)F
Biological Activity: mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
mDPR-Val-Cit-PAB-MMAE TFA | 98.36% | mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MAL-di-EG-Val-Cit-PAB-MMAE | 99.92% | MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Gly3-VC-PAB-MMAE | 98.83% | Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bi-Mc-VC-PAB-MMAE | 98.43% | Bi-Mc-VC-PAB-MMAE consists ADCs linker (Bi-Mc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE, HY-15162). Bi-Mc-VC-PAB-MMAE is a drug-linker conjugate for ADC. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ac-Lys-Val-Cit-PABC-MMAE | 99.94% | Ac-Lys-Val-Cit-PABC-MMAE is a agent-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
OH-Glu-Val-Cit-PAB-MMAE | 99.03% | OH-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (OH-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(Aminooxy)acetamide-Val-Cit-PAB-MMAE | 96.87% | (Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthetic preparation of drug-linker conjugates for ADC. (Aminooxy)acetamide-Val-Cit-PAB-MMAE is conjugated to polyamide via oxime bond formation to form MMAE polyamide conjugate. Then MMAE polyamide conjugate can be conjugated to Trastuzumab, to make ADC. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MC-EVCit-PAB-MMAE | 99.67% | MC-EVCit-PAB-MMAE (Linker-Payload 11) is a drug-linker conjugates for ADC. MC-EVCit-PAB-MMAE contains the ADCs linker (MC-EVCit-PAB) and a potent tubulin polymerization inhibitor MMAE (HY-15162). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VcMMAE (Standard) | 99.95% | VcMMAE (Standard) is the analytical standard of VcMMAE. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mal-Val-Lys-PAB-MMAE | Mal-Val-Lys-PAB-MMAE is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE consists of a Tubulin inhibitor (MMAE) (HY-15162) and a linker (Mal-Val-Lys-PAB). Mal-Val-Lys-PAB-MMAE can be used for synthesis of ADCs. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Aminocaproyl-Val-Cit-PABC-MMAE | 99.89% | Aminocaproyl-Val-Cit-PABC-MMAE is an Drug-linker conjugate for ADC. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
